33

7

39

COCORO

Cognitive Genetics

Collaborative Research Organization
EGUIDE
Effectiveness of GUIdeline for Dissemination and Education in psychiatric treatment
44
182

48
15

1
MRI
7

COCORO
2937
Koshiyama et al Mol Psychiatry

2020

MRI
T1
73%

MRI
Nemoto et al Psychiatry Cli Neurosci 2020
ENIGMA

3

2

6
Morita et al Schizophr
Res 2019)
Morita et al Schizophr Res 2019
Shiino et al Neuropsychopharmacol Rep
2019

104

3

3
2000
COCORO
WAIS

Japanese Adult Reading Test (JART)MRI
Yasuda et al-

Psychiatry Cli Neurosci

2020

4
POGZ
POGZ
Matsumura et al

Nature Comm

2020

3
5
1600
COCOROQOL

1EGUIDEEGUIDE

2016
44

EGUIDE

182
2000

20
EGUIDE
Quality Indicator: QI
QITakaesu et al Psychiatry Cli Neurosci 2019

2

EBM
Minds

Minds
EGUIDE

105

33

(1)
6

NCNP

DSM

RDoC

(2)
EGUIDE

26

EGUIDE

200

(3)
(4)
13

EBM

QI

(5)

(6)

(1)
1)

Sonderby IE, Gustafsson O, Doan NT, Hibar DP, Martin-Brevet S, Abdellaoui A, Ames D,
Amunts K, Andersson M, Armstrong NJ, Bernard M, Blackburn N, Blangero J, Boomsma

106

DI, Bralten J, Brattbak HR, Brodaty H, Brouwer RM, Bülow R, Calhoun V, Caspers S,
Cavalleri G, Chen CH, Cichon S, Ciufolini S, Corvin A, Crespo-Facorro B, Curran JE, Dale
AM, Dalvie S, Dazzan P, de Geus EJC, de Zubicaray GI, de Zwarte SMC, Delanty N, denBraber A, Desrivieres S, Donohoe G, Draganski B, Ehrlich S, Espeseth T, Fisher SE, Franke
B, Frouin V, Fukunaga M, Gareau T, Glahn DC, Grabe H, Groenewold NA, Haavik J,
Haberg A, Hashimoto R (15152), Hehir-Kwa JY, Heinz A, Hillegers MHJ,
Hoffmann P, Holleran L, Hottenga JJ, Hulshoff HE, Ikeda M, Jahanshad N, Jernigan T,
Jockwitz C, Johansson S, Jonsdottir GA, Jönsson EG, Kahn R, Kaufmann T, Kelly S,
Kikuchi M, Knowles EEM, Kolskår KK, Kwok JB, Hellard SL, Leu C, Liu J, Lundervold AJ,
Lundervold A, Martin NG, Mather K, Mathias SR, McCormack M, McMahon KL, McRae A,
Milaneschi Y, Moreau C, Morris D, Mothersill D, Muhleisen TW, Murray R, Nordvik JE,
Nyberg L, Olde Loohuis LM, Ophoff R, Paus T, Pausova Z, Penninx B, Peralta JM, Pike B,
Prieto C, Pudas S, Quinlan E, Quintana DS, Reinbold CS, Marques TR, Reymond A,
Richard G, Rodriguez-Herreros B, Roiz-Santianez R, Rokicki J, Rucker J, Sachdev P,
Sanders AM, Sando SB, Schmaal L, Schofield PR, Schork AJ, Schumann G, Shin J,
Shumskaya E, Sisodiya S, Steen VM, Stein DJ, Steinberg S, Strike L, Teumer A,
Thalamuthu A, Tordesillas-Gutierrez D, Turner J, Ueland T, Uhlmann A, Ulfarsson MO,
van 't Ent D, van der Meer D, van Haren NEM, Vaskinn A, Vassos E, Walters GB, Wang Y,
Wen W, Whelan CD, Wittfeld K, Wright M, Yamamori H, Zayats T, Agartz I, Westlye LT,
Jacquemont S, Djurovic S, Stefansson H, Stefansson K, Thompson P, Andreassen OA;
European Consortium, for the ENIGMA-CNV working group: Dose response of the 16p11.2
distal copy number variant on intracranial volume and basal ganglia. Mol Psychiatry25(3):584-602, 2020.
2)

Grasby KL, Jahanshad N, Painter JN, Colodro-Conde L, Bralten J, Hibar DP, Lind PA,
Pizzagalli F, Ching CRK, McMahon MAB, Shatokhina N, Zsembik LCP, Thomopoulos SI,
Zhu AH, Strike LT, Agartz I, Alhusaini S, Almeida MAA, Alnæs D, Amlien IK, Andersson
M, Ard T, Armstrong NJ, Ashley-Koch A, Atkins JR, Bernard M, Brouwer RM, Buimer EEL,
Bulow R, Bürger C, Cannon DM, Chakravarty M, Chen Q, Cheung JW, Couvy-Duchesne B,
Dale AM, Dalvie S, de Araujo TK, de Zubicaray GI, de Zwarte SMC, den Braber A, DoanNT, Dohm K, Ehrlich S, Engelbrecht HR, Erk S, Fan CC, Fedko IO, Foley SF, Ford JM,
Fukunaga M, Garrett ME, Ge T, Giddaluru S, Goldman AL, Green MJ, Groenewold NA,
Grotegerd D, Gurholt TP, Gutman BA, Hansell NK, Harris MA, Harrison MB, Haswell CC,
Hauser M, Herms S, Heslenfeld DJ, Ho NF, Hoehn D, Hoffmann P, Holleran L, Hoogman
M, Hottenga JJ, Ikeda M, Janowitz D, Jansen IE, Jia T, Jockwitz C, Kanai R, Karama S,
Kasperaviciute D, Kaufmann T, Kelly S, Kikuchi M, Klein M, Knapp M, Knodt AR, Kramer
B, Lam M, Lancaster TM, Lee PH, Lett TA, Lewis LB, Lopes-Cendes I, Luciano M,
Macciardi F, Marquand AF, Mathias SR, Melzer TR, Milaneschi Y, Mirza-Schreiber N,
Moreira JCV, Mühleisen TW, Muller-Myhsok B, Najt P, Nakahara S, Nho K, Olde Loohuis
LM, Orfanos DP, Pearson JF, Pitcher TL, Putz B, Quide Y, Ragothaman A, Rashid FM, Reay
WR, Redlich R, Reinbold CS, Repple J, Richard G, Riedel BC, Risacher SL, Rocha CS, Mota
NR, Salminen L, Saremi A, Saykin AJ, Schlag F, Schmaal L, Schofield PR, Secolin R,
Shapland CY, Shen L, Shin J, Shumskaya E, Sønderby IE, Sprooten E, Tansey KE, Teumer
A, Thalamuthu A, Tordesillas-Gutierrez D, Turner JA, Uhlmann A, Vallerga CL, van derMeer D, van Donkelaar MMJ, van Eijk L, van Erp TGM, van Haren NEM, van Rooij D, vanTol MJ, Veldink JH, Verhoef E, Walton E, Wang M, Wang Y, Wardlaw JM, Wen W, Westlye
LT, Whelan CD, Witt SH, Wittfeld K, Wolf C, Wolfers T, Wu JQ, Yasuda CL, Zaremba D,

107

33

Zhang Z, Zwiers MP, Artiges E, Assareh AA, Ayesa-Arriola R, Belger A, Brandt CL, Brown
GG, Cichon S, Curran JE, Davies GE, Degenhardt F, Dennis MF, Dietsche B, Djurovic S,
Doherty CP, Espiritu R, Garijo D, Gil Y, Gowland PA, Green RC, Hqusler AN, Heindel W,
Ho BC, Hoffmann WU, Holsboer F, Homuth G, Hosten N, Jack CR Jr, Jang M, Jansen A,
Kimbrel NA, Kolskar K, Koops S, Krug A, Lim KO, Luykx JJ, Mathalon DH, Mather KA,
Mattay VS, Matthews S, Mayoral Van Son J, McEwen SC, Melle I, Morris DW, Mueller BA,
Nauck M, Nordvik JE, Nothen MM, O'Leary DS, Opel N, Martinot MP, Pike GB, Preda A,
Quinlan EB, Rasser PE, Ratnakar V, Reppermund S, Steen VM, Tooney PA, Torres FR,
Veltman DJ, Voyvodic JT, Whelan R, White T, Yamamori H, Adams HHH, Bis JC, DebetteS, Decarli C, Fornage M, Gudnason V, Hofer E, Ikram MA, Launer L, Longstreth WT, Lopez
OL, Mazoyer B, Mosley TH, Roshchupkin GV, Satizabal CL, Schmidt R, Seshadri S, Yang
Q; Alzheimer’s Disease Neuroimaging Initiative; CHARGE Consortium; EPIGEN
Consortium; IMAGEN Consortium; SYS Consortium; Parkinson’s Progression Markers
Initiative, Alvim MKM, Ames D, Anderson TJ, Andreassen OA, Arias-Vasquez A, Bastin
ME, Baune BT, Beckham JC, Blangero J, Boomsma DI, Brodaty H, Brunner HG, Buckner
RL, Buitelaar JK, Bustillo JR, Cahn W, Cairns MJ, Calhoun V, Carr VJ, Caseras X, Caspers
S, Cavalleri GL, Cendes F, Corvin A, Crespo-Facorro B, Dalrymple-Alford JC, Dannlowski
U, de Geus EJC, Deary IJ, Delanty N, Depondt C, Desrivieres S, Donohoe G, Espeseth T,
Fernandez G, Fisher SE, Flor H, Forstner AJ, Francks C, Franke B, Glahn DC, Gollub RL,
Grabe HJ, Gruber O, Haberg AK, Hariri AR, Hartman CA, Hashimoto R (360299), Heinz A, Henskens FA, Hillegers MHJ, Hoekstra PJ, Holmes AJ, Hong LE, Hopkins
WD, Hulshoff Pol HE, Jernigan TL, Jonsson EG, Kahn RS, Kennedy MA, Kircher TTJ,
Kochunov P, Kwok JBJ, Le Hellard S, Loughland CM, Martin NG, Martinot JL, McDonald
C, McMahon KL, Meyer-Lindenberg A, Michie PT, Morey RA, Mowry B, Nyberg L,
Oosterlaan J, Ophoff RA, Pantelis C, Paus T, Pausova Z, Penninx BWJH, Polderman TJC,
Posthuma D, Rietschel M, Roffman JL, Rowland LM, Sachdev PS, Samann PG, Schall U,
Schumann G, Scott RJ, Sim K, Sisodiya SM, Smoller JW, Sommer IE, St Pourcain B, Stein
DJ, Toga AW, Trollor JN, Van der Wee NJA, van 't Ent D, Völzke H, Walter H, Weber B,
Weinberger DR, Wright MJ, Zhou J, Stein JL, Thompson PM, Medland SE; Enhancing
NeuroImaging Genetics through Meta-Analysis Consortium (ENIGMA) Genetics working
group:

The

genetic

architecture

of

the

human

cerebralcortex.

Science367(6484):1340(eaay6690), 2020.
3)

Shiino T, Miura K, Fujimoto M, Kudo N, Yamamori H, Yasuda Y, Ikeda M, Hashimoto R:
Comparison of eye movements in schizophrenia and autism spectrum disorder.
Neuropsychopharmacol Rep 40(1):92-95, 2020.

4)

Yasuda Y, Okada N, Nemoto K, Fukunaga M, Yamamori H, Ohi K, Koshiyama D, Kudo N,
Shiino T, Morita S, Morita K, Azechi H, Fujimoto M, Miura K, Watanabe Y, Kasai K,
Hashimoto R: Brain morphological and functional features in cognitive subgroups of
Schizophrenia. Psychiatry Clin Neurosci 74(3):191-203, 2020.

5)

Matsumura K, Seiriki K, Okada S, Nagase M, Ayabe S, Yamada I, Furuse T, Shibuya H,
Yasuda Y, Yamamori H, Fujimoto M, Nagayasu K, Yamamoto K, Kitagawa K, Miura H,
Gotoda-Nishimura N, Igarashi H, Hayashida M, Baba M, Kondo M, Hasebe S, Ueshima K,
Kasai A, Ago Y, Hayata-Takano A, Shintani N, Iguchi T, Sato M, Yamaguchi S, Tamura M,
Wakana S, Yoshiki A, Watabe AM, Okano H, Takuma K, Hashimoto R, Hashimoto H,
Nakazawa T: Pathogenic POGZ mutation causes impaired cortical development andreversible autism-like phenotypes. Nat Commun 11(1):859, 2020.

108

6)

Nemoto K, Shimokawa T, Fukunaga M, Yamashita F, Tamura M, Yamamori H, Yasuda Y,
Azechi H, Kudo N, Watanabe Y, Kido M, Takahashi T, Koike S, Okada N, Hirano Y,
Onitsuka T, Yamasue H, Suzuki M, Kasai K, Hashimoto R, Arai T: Differentiation ofschizophrenia using structural MRI with consideration of scanner differences: A real-world
multi-site study. Psychiatry Clin Neurosci 74(1):56-63, 2020.

7)

Baba M, Yokoyama K, Seiriki K, Naka Y, Matsumura K, Kondo M, Yamamoto K, Hayashida
M, Kasai A, Ago Y, Nagayasu K, Hayata-Takano A, Takahashi A, Yamaguchi S, Mori D,
Ozaki N, Yamamoto T, Takuma K, Hashimoto R, Hashimoto H, Nakazawa T: Psychiatricdisorder-related behavioral phenotypes and cortical hyperactivity in a mouse model of 3q29
deletion syndrome. Neuropsychopharmacology 44(12):2125-2135, 2019.

8)

Matsumura K, Baba M, Nagayasu K, Yamamoto K, Kondo M, Kitagawa K, Takemoto T,
Seiriki K, Kasai A, Ago Y, Hayata-Takano A, Shintani N, Kuriu T, Iguchi T, Sato M, Takuma
K, Hashimoto R, Hashimoto H: Autism-associated protein kinase D2 regulates embryoniccortical neuron development. Biochem Biophys Res Commun 519(3):626-632, 2019.

9)

Takaesu Y, Watanabe K, Numata S, Iwata M, Kudo N, Oishi S, Takizawa T, Nemoto K,
Yasuda Y, Tagata H,

Tsuboi T, Tsujino N, Hashimoto N, Matsui Y, Hori H, Yamamori H,

Sugiyama N, Suwa T, Kishimoto T,

Hishimoto A, Usami M, Furihata R, Iwamoto K,

Fujishiro H, Nakamura T, Mizuno K, Inagaki T, Katsumoto E,

Tomita H, Ohi K, Muraoka

H, Atake K, Iida H, Nagasawa T, Fujita J, Yamamura S, Onitsuka T, Murata A,
Takayanagi Y, Noda H, Matsumura Y, Takezawa K, Iga J, Ichihashi K, Ogasawara K,
Yamada H, Inada K, Hashimoto R: Improvement of psychiatrists’ clinical knowledge of thetreatment guidelines for schizophrenia and major depressive disorders using the“Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment(EGUIDE) ” project: a nationwide dissemination, education and evaluation study.
Psychiatry Clin Neurosci 73(10):642-648, 2019.
10) Oya K, Sakuma K, Esumi S, Hashimoto Y, Hatano M, Matsuda Y, Matsui Y, Miyake N,
Nomura I, Okuya M, Iwata N, Kato M, Hashimoto R, Mishima K, Watanabe N, Kishi T:
Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinicallystable patients with bipolar disorder: A systematic review and meta-analysis of double-blind,randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacol
Rep 39(3):241-246, 2019.
11) Ohi K, Sumiyoshi C, Fujino H, Yasuda Y, Yamamori H, Fujimoto M, Sumiyoshi T,
Hashimoto R: A 1.5-year longitudinal study of social activity in patients with schizophrenia.
Front Psychiatry section Schizophrenia 10:567, 2019.
12) Morita K, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Azechi H, OkadaN,
Koshiyama D, Shiino T, Fukunaga M, Watanabe Y, Ikeda M, Kasai K, Hashimoto R: Eyemovement characteristics of schizophrenia and their association with cortical thickness.
Psychiatry Clin Neurosci 73(8): 508-509, 2019.
13) Morita K, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Azechi H, Okada N,
Koshiyama D, Ikeda M, Kasai K, Hashimoto R: Eye movement abnormalities and theirassociation with cognitive impairments in schizophrenia. Schizophr Res 209:255-262, 2019.
14) Ikeda M, Takahashi A, Kamatani Y, Momozawa Y, Saito T, Kondo K, Shimasaki A, Kawase
K, Sakusabe T, Iwayama Y, Toyota T, Wakuda T, Kikuchi M, Kanahara N, Yamamori H,
Yasuda Y, Watanabe Y, Hoya S, Aleksic B, Kushima I, Arai H, Takaki M, Hattori K, Kunugi
H, Okahisa Y, Ohnuma T, Ozaki N, Someya T, Hashimoto R, Yoshikawa T, Kubo M, Iwata
N: Genome-Wide Association Study Detected Novel Susceptibility Genes for Schizophrenia

109

33

and Shared Trans-Populations/Diseases Genetic Effect. Schizophr Bull 45(4):824-834, 2019.
15) van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, Pearlson GD, Yao N,
Fukunaga M, Hashimoto R (10910), Okada N, Yamamori H, Clark VP, Mueller
BA, de Zwarte SMC, Ophoff RA, van Haren NEM, Andreassen OA, Gurholt TP, Gruber O,
Kraemer B, Richter A, Calhoun VD, Crespo-Facorro B, Roiz-Santianez R, TordesillasGutierrez D, Loughland C, Catts S, Fullerton JM, Green MJ, Henskens F, Jablensky A,
Mowry BJ, Pantelis C, Quide Y, Schall U, Scott RJ, Cairns MJ, Seal M, Tooney PA, Rasser
PE, Cooper G, Shannon Weickert C, Weickert TW, Hong E, Kochunov P, Gur RE, Gur RC,
Ford JM, Macciardi F, Mathalon DH, Potkin SG, Preda A, Fan F, Ehrlich S, King MD, De
Haan L, Veltman DJ, Assogna F, Banaj N, de Rossi P, Iorio M, Piras F, Spalletta G, PomarolClotet E, Kelly S, Ciufolini S, Radua J, Murray R, Marques TR, Simmons A, Borgwardt S,
Schonborn-Harrisberger F, Riecher-Rossler A, Smieskova R, Alpert KI, Bertolino A,
Bonvino A, Di Giorgio A, Neilson E, Mayer AR, Yun JY, Cannon DM, Lebedeva I, Tomyshev
AS, Akhadov T, Kaleda V, Fatouros-Bergman H, Flyckt L; Karolinska Schizophrenia Project,
Rosa PGP, Serpa MH, Zanetti MV, Hoschl C, Skoch A, Spaniel F, Tomecek D, McIntosh AM,
Whalley HC, Knöchel C, Oertel-Knöchel V, Howells FM, Stein DJ, Temmingh HS, Uhlmann
A, Lopez-Jaramillo C, Dima D, Faskowitz JI, Gutman BA, Jahanshad N, Thompson PM,
Turner JA: Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging
Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of
the Disease Process? Biol Psychiatry 85(7):e35-e39, 2019.
16) Ono S, Miura K, Kawamura T, Kizuka T: Asymmetric smooth pursuit eye movements andvisual motion reaction time. Physiol Rep 7(14):e14187, 2019.
17) Kunii Y, Hino M, Matsumoto J, Nagaoka A, Nawa H, Kakita A, Akatsu H, Hashizume Y,
Yabe H: Differential protein expression of DARPP-32 versus Calcineurin in the prefrontal
cortex and nucleus accumbens in schizophrenia and bipolar disorder. Sci Rep 16;9(1):14877,
2019.
18) Ohnishi T, Balan S, Toyoshima M, Maekawa M, Ohba H, Watanabe A, Iwayama Y, Fujita Y,
Tan Y, Hisano Y, Shimamoto-Mitsuyama C, Nozaki Y, Esaki K, Nagaoka A, Matsumoto J,
Hino M, Mataga N, Hayashi-Takagi A, Hashimoto K, Kunii Y, Kakita A, Yabe H, Yoshikawa
T: Investigation of betaine as a novel psychotherapeutic for schizophrenia. EBioMedicine
45:432-446, 2019.
19) Ono CT, Yu Z, Kikuchi Y, Kunii Y, Hino M, Matsumoto J, Nagaoka A, Ito J, Iwasaki Y,
Hagihara H, Miyakawa T, Yoshida M, Saito Y, Niwa SI, Yabe H, Kakita A, Tomita H:
Minimal amount of tissue-based pH measurement to improve quality control inneuropsychiatric post-mortem brain studies. Psychiatry Clin Neurosci 73(9):566-573, 2019.
(2)
1

Morita K, Miura K, Kasai K, Hashimoto R: Eye movement characteristics in schizophrenia:
A recent update with clinical implications. Neuropsychopharmacol Rep 40(1):2-9, 2020.

2

Nakazawa T, Hashimoto R, Takuma K, Hashimoto H: Current Perspective: Modeling of
psychiatric disorders using induced pluripotent stem cell-related technologies. J Pharmacol
Sci 140(4):321-324, 2019.

3
31(1):1
4

2020.
13(1):27-34 2020.

5

EGUIDE110

272(2):188-193 2020.
637(150-151

)

2019.

7

AI

48(9):1043-1047

2019.
8

22(5):515-519
2019.

9

22(4)
341-346

2019.

(3)
1)

Miura K, Takemura A, Taki M, Kawano K

Chapter 24 Model of optokinetic responses

involving two different visual motion processing pathways. In Progress in Brain Research,
Vol. 248, Mathematical Modelling in Motor Neuroscience: State of the Art and Translation
to the Clinic. Ocular Motor Plant and Gaze Stabilization Mechanisms, Edited by Ramat S
and Shaikh AG, Academic Press, pp329-340, 2019.
(4)
1)

iPS
2019

B

2)

2020

2019
2019
2020

3)

EGUIDE

31
2020

4)

QI
2019
2019

2020

5)

H31
MRI
2019
2020

6)

H31
2019
2020

7)

H31

2019

2020

8)

H31

2019
9)

2020
2019

111

33

2020
10)

31
2020

(5)
(6)
1)

EGUIDE
EBM

Minds

https://minds.jcqhc.or.jp/s/dissemination_and_evaluation_3. 2020

(1)
1)

Hashimoto R: The ENIGMA and COCORO:Replication and Harmonization. Symposium"
International neuroimaging big data collaborations: ENIGMA and COCORO”. 6th Congressof Asian College of Neuropsychopharmacology (AsCNP), Fukuoka, 2019.10.11.

2)

Miura K: Two frame apparent motion presented with inter-stimulus interval reverses
ocular and neuronal responses in macaque monkeys. The Kyoto Symposium on the Eye andHead Movement Control Systems Pre-NCM(2019), Kyoto, 2019.4.21.

3)

14
2019.4.19.

4)
-

-

14

2019.4.20.
5)115
2019.6.21.
6)45

2019.8.30.

7)39
2019.9.21.

8)Genomewide association study detected novel susceptibility genes for schizophrenia and sharedtrans-populations/diseases genetic effect CNP
29
2019.10.12.
9)
29
10)
JSNP/JSCNP

112

2019.10.11.

49

29

2019.10.12.
(2)
1)

Sumiyoshi C, Ohi K, Fujino H, Yamamori H, Kudo N, Azechi H, Fujimoto M, Yasuda Y,
Sumiyoshi T, Hashimoto R: Association between Work Status and Subjective Aspects ofRecovery in Patients with Schizophrenia: A longitudinal study. Schizophrenia International
Research Society (SIRS), Orlando, 2019.4.13.

2)

Fukuda M, The collaborative team for “A co-production project to develop a practicalguidance for patient-centered and life-oriented recovery of schizophrenia”: A co-productive
development of a practical guidance for patient-centered and life-oriented recovery ofschizophrenia in Japan. 7th European Conference on Schizophrenia Research (ECSR),
Berlin, 2019.9.27.

3)

Fujimoto M, Taomoto D, Katakami S, Omi T, Hashimoto R, Yamamori H, Yasuda Y, Makino
T, Yoshikawa H, Iwase M, Ikeda M: Clozapine-induced seizure complicated with vertebral
fracture, leg paralysis and pulmonary embolism in a patient with treatment-resistantschizophrenia. 6th Congress of Asian College of Neuropsychopharmacology (AsCNP),
Fukuoka, 2019.10.13.

4)

Aoki S, Matsumoto J, Otani K, Toda W, Motoya R, Itagaki S, Miura I, Yabe H: Pilot
investigation of group behavioral activation for chronic low back pain (GBA-P) 9th World
Congress of Behavioural and Cognitive Therapies, Berlin, 2019.7.20.

5)14

2019.4.19.

6)
EGUIDE2
14

2019.4.20.
7)

5

CEPD

2019.5.11.

8)CPCJ Clozapine Pharmacogenomics Consortium of Japan
Mendelian
Randomization

115

2019.6.20.

9)

Clozapine
115
2019.6.20.

10)
EGUIDE115

2019.6.21.

11)

EGUIDE1
115

2019.6.21.

113

33

12)
115

2019.6.21.

13)

115
2019.6.21.

14)

EGUIDEEGUIDE115

2019.6.21.
15)

115
2019.6.21.

16)
115

2019.6.21.

17)
41
2019.6.22.
18)

41

2019.6.23.

19)
41
2019.6.23.
20)
41

2019.6.23.

21)
41

2019.6.23.

22)
EGUIDE--

16

2019.7.5.

23)
GDNF)
16

2019.7.5.

24)

16

2019.7.6.

25)
16

2019.7.6.

26) Matsumura K, Seiriki K, Nagase M, Ayabe S, Yamada I, Furuse T, Yamamoto K, Kitagawa

114

K, Iguchi T, Sato M, Yamaguchi S, Tamura M, Wakana S, Yoshi A, Watabe AM, Okano H,
Takuma K, Hashimoto R, Hashimoto H, Nakazawa T: ASD-related de novo POGZ
mutations disrupt cortical neuronal differentiation.
42
62

Neuro2019)2019.7.26.

27) Yamamoto K, Kuriu T, Nakazawa T, Matsumura K, Nayasu K, Baba M, Yamamori H,
Yasuda Y, Fujimoto M, Tsurusaki Y, Matsumoto N, Takuma K, Hashimoto R, Hashimoto H:
Pathological analysis of neurons from iPS cells derived from patients with schizophrenia ina multiple family.
42
62
Neuro2019),
2019.7.26.
28) Shiino T, Miura K, Fujimoto M, Kudo N, Yamamori H, Yasuda Y, Ikeda M, Hashimoto R:
Comparison of eye movement in Autism Spectrum Disorder and Schizophrenia.
42
62

Neuro2019)2019.7.27.

29) Takamura T, Nakamura T, Yoshinaga K, Ogata Y, Ozaki N, Kasai K, Hashimoto R,
Hanakawa T: Multi-site Harmonization of Resting-state functional connectivity MRI data
improves classification of major depressive disorder.
3
2019.9.6.
30)
DTI
/

3
2019.9.7.

31)
3

2019.9.7.

32)
39
2019.9.21.
33)
Quality Indicator

EGUIDE3

2019.9.21.

34) Shixing B, Watanabe Y, Tomiyama N, Takahashi H, Hashimoto R, Hata J

The comparisonof q-space myelin map, fractional anisotropy and apparent diffusion coefficient values
between normal young and old ages.
47
2019.9.21.
35)
JSNP/JSCNP
49
29

2019.10.12.

36)
EGUIDE49

2019.10.12.

37)
49
2019.10.12.
38)(EGUIDE

)

115

33

2

2

49

2019.10.13.

39)(EGUIDE
)

1

2

49

2019.1013.

40)

F2
58
2019.10.25.

41)
53

2019.10.31.

42)
49

2019.11.28.

43)
49

2020.1.18.

44)
2020

2020.2.4.

45) Hayashi K, Matsumoto N, Matsuda K, Miura K, Yamane S, Matsuo S, Yanai K, Eldridge
MAG, Richard SC, Richmond BJ, Nagai Y, Miyakawa N, Minamimoto T, Okada M, Kawano
K, Sugase-Miyamoto Y Neural coding of facial images with different skin textures in thetemporal lobe of macaque monkeys.
Neuro2019)42

62

2019.7.26.

46) Sugita Y, Miura K, Furukawa T: Photoreceptor ribbon synapse may regulate light
adaptation in the visual system underlying optokinetic responses.
42
62

Neuro2019)47) Takemura A, Kawano K, Miura K

2019.7.26.

2

MST

42
Neuro2019)62

2019.7.27.

48) Chen C-Y, Matrov D, Richard Veale R, Miura K, Isa T: Eye movement tracking in headfixed common marmosets.
9
2020.2.14.
49)
.
115

2019.6.20.

50)
SPECT

3D-SRT.

115

2019.6.20.
51)
115

2019.6.20.

52)
115
53)

116

2019.6.20.

115
2019.6.20.
54)

115

2019.6.20.

55)
115
2019.6.21.
56)

6
115
2019.6.21.

57)
115

2019.6.21.

58)
115
2019.6.21.
59)

115

2019.6.21.

60)
49
2019.11.28.
61)
49

2019.11.28.

62)

49

2019.11.28.

63)
Mismatch Negativity MMN
49

2019.11.30.

(3)
1)

17

IGC

13

COCORO

2019.6.1.
2)

17

IGC

13

COCORO

18

IGC

14

COCORO

2019.6.2.
3)
2019.12.7.
4)

18

IGC

14

COCORO

2019.12.7.
5)

AI

17

IGC

13

COCORO

117

33

2019.6.2.
6)2
7)

2019.11.26.

AI
14

:

COCORO

18

IGC

IGC

14

2019.12.7.

8)

17

IGC

13

COCORO

2019.6.1.
9)

MRI
COCORO

QC

18

AMED

2019.11.19.

2019.12.7.

(4)
1)
NCNP,
2019.8.22.

Psychiatry and Clinical Neuroscience

2)

-

NCNP,

IRCN

Molecular

Psychiatry
3)
2020.2.19.

-

NCNP

Nature Communications

4)

NCNP
2019.5.7.

5)

QI
QI
2019.5.18.

6)115
2019.6.22.

7)
2019.7.5.
8)
50

IBIC

NCNP)

2019.7.23.

9)8

2019.9.1.

1)
2019.6.25.
2)

DSM

RDoC

6

NCNP

2019.8.23.
3)
2019.9.6.
4)

18

118

AMED

2019.10.17.
5)
Clozapine
19

2019.11.9.

6)
19
2019.11.9.
7)

39
2019.11.19.

8)
2019.11.28.
9)
4

2020.2.7.

(1)
(2)
1)
50
EGUIDE
2)

PCN

3)
4)
5)
EGUIDE
6)
7)
8)
9)
(3)
1)

Hashimoto R: Symposium"International neuroimaging big data collaborations: ENIGMA
and COCORO". 6th Congress of Asian College of Neuropsychopharmacology (AsCNP),
Fukuoka, 2019.10.11.

2)

14
2019.4.19.

3)

41

4)

8

5)

JSNP/JSCNP

2019.6.23.
I

41

2019.6.23.
49

29

2019.10.12.

119

33

(4)
1)

Psychiatry and Clinical Neuroscience2)

Neuropsychopharmacology Reports

(1)
1)

14
2019.4.19.

2)
2019.5.19.
3)

2019.5.26.

4)115
2019.6.21.

5)

16

EGUIDE2019.7.7.
6)

16

EGUIDE2019.7.6.

7)

EGUIDE2019.10.5.

8)

EGUIDE

9)EGUIDE2019.10.6.

2019.10.5.
10)EGUIDE

11)

49

12)

EGUIDE2019.10.6.
29
2019.12.13.

2019.10.19.
13)

EGUIDE

14)

2019.10.20.
EGUIDE,2019.10.19.
15)

EGUIDE

16)

2019.10.20.
EGUIDE2019.10.27.

17)

EGUIDE2019.11.2.

18)

EGUIDE

19)

EGUIDE2019.11.2.

20)

EGUIDE2019.11.3.

21)

EGUIDE2019.11.10.

120

2019.11.3.

22)

EGUIDE2019.12.14.

23)

EGUIDE2019.12.15.
24)
EGUIDE2019.12.14.
25)

EGUIDE26)

2019.12.15.
EGUIDE2019.12.21.

27)

EGUIDE28)

2019.12.22.
EGUIDE2019.12.21.

29)

EGUIDE2019.12.22.

(2)
1)

14
2019.4.19.

2)
2019.5.19.
3)
2019.5.26.
4)115

2019.6.21.

5)

EGUIDE
16

2019.7.6.

6)49
2019.10.13.

7)

EGUIDE2019.10.19.

8)

EGUIDE2019.10.19.

9)

EGUIDE2019.10.19.

10)

EGUIDE2019.10.20.

11)

EGUIDE2019.10.20.

12)

EGUIDE2019.10.27.

13)

EGUIDE2019.10.27.

14)

EGUIDE2019.10.27.

121

33

15)

EGUIDE2019.11.10.

16)

EGUIDE2019.11.10.

17)

EGUIDE2019.11.10.

18)

EGUIDE2019.12.21.

19)

EGUIDE2019.12.21.

20)

EGUIDE2019.12.21.

21)

EGUIDE2019.12.22.

22)

EGUIDE2019.12.22.

23)

EGUIDE2019.12.22.

24)
2020.1.11.

1)

17

IGC

13

COCORO2)

2019.6.1-2.
EGUIDE2019.10.19.
3)

EGUIDE2019.10.20.

4)

EGUIDE2019.10.27.

5)

EGUIDE2019.11.10.

6)

18

7)

IGC

14

COCORO

2019.12.7.
EGUIDE2019.12.21.
8)

EGUIDE2019.12.22.

122